Cellix

Cerba Research is the merge of Barc Lab, Histalim and Cerba Xpert. All 3 entities are part of the Cerba HealthCare group and have decided to join forces under one name.

Cerba Research provides the highest quality specialized laboratory and diagnostic solutions while leveraging patient data and scientific insight to shape and advance clinical trials. With our global footprint and access to leading regional labs, data, patients, technology, and partnered resources, we support global biotech, pharma, and IVD organizations to improve the lives of patients around the world.

From the translation of preclinical to clinical, through commercialization, our expert scientists collaborate with you to optimize your therapeutic development and obtain critical insights earlier. We help accelerate your therapies through the development of highly specialized custom assays, deep biomarker expertise, and a passion for scientific innovation across complex therapeutic areas. Our global network of leading, specialty laboratories ensures you have access to quality data and can reach your patients. Together, we’ll improve patients’ lives around the globe.

Taros Chemicals GmbH & Co. KG, an independent, privately owned contract research organization based in Dortmund, Germany, has been serving the chemistry needs of pharmaceutical, chemical and biotech companies since its inception in 1999. A forerunner in the early German biotech scene, Taros can claim more than 13,000 syntheses, research and process chemistry projects delivered to-date to an increasingly expanding and diverse base of global customers.

In its state-of-the-art facilities in Dortmund's prestigious BioMedizinZentrum (BMZ), the hub of top ranking biotech organizations, Taros'​ team of highly creative and skilled scientists, aided by its state-of-the-art laboratory facilities, are wholly committed to solving a wide range of customers'​ R&D problems in innovative drug discovery, medicinal chemistry and classical synthetic chemistry. Their collective knowledge and experience in industrial organic chemistry, span a period of over 160 years, and in active drug discovery, around 60 years, covering the full spectrum, from big pharma to biotechnology. Taros is active today in therapeutic areas which include oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious diseases, in all small-molecule target classes.

Our company's mission is to enhance the quality of human lives by providing advanced and innovative chemistry-driven technologies to our customers R&D endeavors in the global marketplace. We strive hard to provide creative, holistic and cost-effective solutions with the highest level of quality, reliability and integrity. We continuously endorse loyalty and commitment in our employees, inspiring them to provide exceptional value to our customers'​ R&D processes, by anticipating hurdles before they arise, by foreseeing potential cost and lead time reductions, and most importantly, by facilitating their competitive and "early to market"​ advantage.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. Our proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring.

Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$6.5 billion molecular diagnostics market. Biocartis employs over 500 people and is headquartered in Mechelen, Belgium. Further information? Visit www.biocartis.com

Eurofins Scientific is an international life sciences company, providing a unique range of analytical testing services to clients across multiple industries, to make life and the environment safer, healthier and more sustainable. From the food you eat to the medicines you rely on, Eurofins works with the biggest companies in the world to ensure the products they supply are safe, their ingredients are authentic and labelling is accurate. Eurofins is a global leader in food, environmental, pharmaceutical and cosmetic product testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies.

In over just 30 years, Eurofins has grown from one laboratory in Nantes, France to over 50,000 staff across a network of more than 900 independent companies in over 50 countries, operating more than 800 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing.

Eurofins is one of the fastest growing listed European companies. Since its IPO on the French stock exchange in 1997, Eurofins’ sales have increased by 35% each year (in compound average) to over EUR 4.5 billion in 2019.

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.